Currently, Maruishi is applying for a manufacture and marketing license for Remifentanil injection, which is widely used as an opioid analgesic (µ-opioid receptor agonist) to manage general anaesthesia.
Remifentanil injection is an ultra short-acting analgesic used for general anaesthesia characterized by its potent analgesic action together with its superior ability to rapidly regulate pain.
After Maruishi acquires a license for the manufacturing and marketing of this drug, it will be responsible for manufacturing the product, while Daiichi Sankyo will handle the drug’s marketing.
Promotion activities of the product will be carried out jointly by both the companies.
Daiichi Sankyo provides new products and services in more than 20 countries around the world.
The company, which has 17,000 employees worldwide, creates new and generic medicines, and new methods of drug discovery and delivery.